Cargando…

Mitogen-activated kinases in psoriatic arthritis: differences in activation and distinct regulation by etanercept therapy

Detalles Bibliográficos
Autores principales:	Lories, RJU, Derese, I, Luyten, FP, de Vlam, K
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834087/ http://dx.doi.org/10.1186/ar1609

Ejemplares similares

Noggin haploinsufficiency influences severity of arthritis in different mouse models
por: Daans, M, et al.
Publicado: (2005)

Peripheral joint ankylosis in the spontaneous model of arthritis in DBA/1 mice is genetically associated with BMP signaling
por: Carter, S, et al.
Publicado: (2011)

Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments
por: Vandendorpe, Ann-Sophie, et al.
Publicado: (2019)

Molecular mechanisms involved in a differential association of Frzb biology with osteoarthritis and osteoporosis
por: Lories, Rik JU, et al.
Publicado: (2007)

Distinct biological properties of human mesenchymal stem cells from different sources
por: De Bari, C, et al.
Publicado: (2005)

Orthopaedic interventions in patients with psoriatic arthritis: a descriptive report from the SPAR cohort
por: Haque, Naba, et al.
Publicado: (2016)

Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
por: Lazareva, Arina, et al.
Publicado: (2011)

Systematic review of the use of CRP in clinical trials for psoriatic arthritis: a concern for clinical practice?
por: Houttekiet, Charlotte, et al.
Publicado: (2022)

In vitro effects of etanercept on the development of different T cell subsets in patients with juvenile idiopathic arthritis
por: Cimaz, Rolando, et al.
Publicado: (2011)

Etanercept discontinuation in a cohort of juvenile idiopathic arthritis patients: etanercept inefficacy but not intolerance is associated with oral corticosteroid use
por: Southwood, TR, et al.
Publicado: (2008)

Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritis
por: Rexhepi, Sylejman, et al.
Publicado: (2012)

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2011)

Essential role for migration inhibitory factor in IL-1 activation of mitogen-activated protein kinases
por: Morand, E, et al.
Publicado: (2003)

Macrophage dysfunction in Psoriatic Arthritis
por: Wenink, Mark H, et al.
Publicado: (2011)

Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
por: Sara, De Sanctis, et al.
Publicado: (2011)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

Discontinuation of etanercept after clinical remission in patients with juvenile idiopathic arthritis
por: Cohen, Jean-David, et al.
Publicado: (2012)

Triple jump for the optimal management of psoriatic arthritis: diet, sleep and exercise – a review
por: Lubrano, Ennio, et al.
Publicado: (2023)

Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2012)

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)
por: Horneff, G, et al.
Publicado: (2008)

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis
por: Prince, FHM, et al.
Publicado: (2008)

The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
por: Trachana, M, et al.
Publicado: (2011)

Indirect comparison of etanercept and abatacept efficacy and safety in patients with polyarticular juvenile idiopathic arthritis
por: Loskutova (Konopelko), OU, et al.
Publicado: (2014)

Etanercept-Induced Hypoglycemia in a Patient With Psoriatic Arthritis and Diabetes
por: Pfeifer, Emily C., et al.
Publicado: (2017)

National survey of patients with psoriatic arthritis in Spain: disease activity, pharmacological therapy and impact on quality of life
por: Cañete, J D, et al.
Publicado: (2010)

An in-depth analysis of young people's experience of their juvenile idiopathic arthritis (JIA) once receiving Etanercept
por: Livermore, P, et al.
Publicado: (2008)

Evolution of patient characteristics in the era of biologic treatment of psoriatic arthritis: 18-year Belgian experience from the Leuven Spondyloarthritis Biologics Cohort (BioSPAR)
por: Ishchenko, Alla, et al.
Publicado: (2021)

Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis
por: Susic, G, et al.
Publicado: (2008)

Multicentric Castleman's Disease (CD) in juvenile idiopathic arthritis (JIA) treated with etanercept: coincidence or causal relationship?
por: Rossi, L, et al.
Publicado: (2008)

PReS-FINAL-2096: Herpes virus infections in patients with juvenile idiopathic arthritis (JIA) treated with etanercept
por: Nicolai, R, et al.
Publicado: (2013)

Tumour necrosis factor-α levels are elevated in adolescent patients with juvenile idiopathic arthritis on etanercept therapy
por: Radziszewska, Anna, et al.
Publicado: (2014)

Impaired dendritic cell proinflammatory cytokine production in psoriatic arthritis
por: Wenink, Mark H, et al.
Publicado: (2011)

PReS-FINAL-2106: Clinical psoriatic arthritis of specific children
por: Chebisheva, S, et al.
Publicado: (2013)

Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
por: Kivelevitch, Dario, et al.
Publicado: (2014)

A Case of Sclerosing Mesenteritis during Etanercept Therapy for Psoriatic Arthritis
por: Bukiej, Aleksandra
Publicado: (2020)

Two-year follow-up results after re-administration of etanercept in active ankylosing spondylitis
por: Baraliakos, X, et al.
Publicado: (2005)

Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 772 patients
por: Verazza, Sara, et al.
Publicado: (2014)

TNF-alpha induced chondrocyte apoptosis in NF-κB suppression is augmented by inhibition of p38 mitogen-activated protein kinase or phosphatidylinositol 3-kinase
por: Kim, H
Publicado: (2003)

Mapping out the mitogen activated protein kinase pathway
por: Firestein, GS
Publicado: (2004)

The role of etanercept in juvenile dermatomyositis (JDMS) in children
por: Green, Katherine L, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_j3esv45m87parlb0kf3mo85mju